Catecholamine Response to Methamphetamine is Related to Glucocorticoid Levels but not to Pleasurable Subjective Response

Introduction: Corticosteroids may modulate addiction. We previously described subjective, physiological, and endocrine effects of 0.5 mg/kg of intravenous methamphetamine after augmenting cortisol level with hydrocortisone or blocking cortisol response with the corticosteroid synthesis inhibitor metyrapone in a double-blind, balanced crossover study. Although the pharmacologic manipulations produced the expected hormonal changes, pleasurable subjective effects of methamphetamine were unchanged. Metyrapone was followed by frequent premature ventricular complexes (PVCs) in two subjects during methamphetamine administration. In order to better understand these results, we examined changes in two plasma catecholamine metabolites, homovanillic acid (HVA) and 3-methoxy-4-hydroxyphenylglycol (MHPG), and their relationship to the previously reported hormonal changes and physiological and subjective responses. Methods: Plasma from 10 methamphetamine subjects from the earlier study was assayed for HVA and MHPG by high performance liquid chromatography. Results: HVA levels were greater after hydrocortisone or metyrapone pretreatment compared to placebo, and MHPG levels were greater after metyrapone pretreatment. Hydrocortisone pretreatment diminished HVA and MHPG increases after methamphetamine (perhaps explaining the lack of expected increase in pleasurable effects), but metyrapone did not. HVA and MHPG concentrations were not correlated with pleasurable drug effects but were inversely related to reports of ”Bad Drug Effect.” Increases in MHPG and DHEA concentrations were positively correlated. Metyrapone pre-treated subjects with PVCs had lower HVA and MHPG concentrations. Conclusion: Raising cortisol concentration and blocking cortisol synthesis did not produce opposite effects, perhaps because of metyrapone’s effect on the hypothalamic-pituitary-adrenal axis, its stress-like effects, and its effects on neurosteroids.

References

• 1 Alesci S, Bornstein S R. Intraadrenal mechanisms of DHEA regulation: a hypothesis for adrenopause.  Exp Clin Endocrinol Diabetes . 2001;  109 75-82
• 2 Amin F, Davidson M, Davis K L. Homovanillic acid measurement in clinical research: a review of methodology.  Schizophr Bull. 1992;  18 123-148
• 3 Amit Z, Brown Z W. Actions of drugs of abuse on brain reward systems: a reconsideration with specific attention to alcohol.  Pharmacol Biochem Behav . 1982;  17 233-238
• 4 Barrett J E, Zhang L, Ahlers S T, Wojnicki F H. Acute and chronic effects of corticotropin-releasing factor on schedule-controlled responding and neurochemistry of pigeons.  J Pharmacol Exp Ther . 1989;  250 788-794
• 5 Barrett S P, Boileau I, Okker J, Pihl R O, Dagher A. The hedonic response to cigarette smoking is proportional to dopamine release in the human striatum as measured by positron emission tomography and [11C]raclopride.  Synapse. 2004;  54 65-71
• 6 Berger S P, Hall S, Mickalian J D, Reid M S, Crawford C A, Delucchi K, Carr K, Hall S. Haloperidol antagonism of cue-elicited cocaine craving.  Lancet. 1996;  347 504-508
• 7 Brown Z W, Amit Z, Sinyor D, Rockman G E, Ogren S O. Suppression of voluntary ingestion of morphine by inhibition of dopamine-beta-hydroxylase.  Arch Int Pharmacodyn Ther. 1978;  232 102-110
• 8 Castellanos F X, Elia J, Kruesi M J, Marsh W L, Gulotta C S, Potter W Z, Ritchie G F, Hamburger S D, Rapoport J L. Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/hyperactivity disorder.  Neuropsychopharmacology . 1996;  14 125-137
• 9 CD C. Increasing morbidity and mortality associated with abuse of methamphetamine - United States, 1991-1994.  MMWR. 1995;  44 882-887
• 10 Curtis A L, Lechner S M, Pavcovich L A, Valentino R J. Activation of the locus coeruleus noradrenergic system by intracoerulear microinfusion of corticotropin-releasing factor: effects on discharge rate, cortical norepinephrine levels and cortical electroencephalographic activity.  J Pharmacol Exp Ther . 1997;  281 163-172
• 11 Davidson M, Losonczy M F, Mohs R C, Lesser J C, Powchik P, Freed L B, Davis B M, Mykytyn V V, Davis K L. Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients.  Neuropsychopharmacology . 1987;  1 17-23
• 12 Davis W M, Smith S G, Khalsa J H. Noradrenergic role in the self-administration of morphine or amphetamine.  Pharmacol Biochem Behav . 1975;  3 477-484
• 13 Davis W M, Smith S G, Werner T E. Noradrenergic role in the self-administration of ethanol.  Pharmacol Biochem Behav. 1978;  9 369-374
• 14 Debonnel G, de Montigny C. Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders.  Life Sci . 1996;  58 721-734
• 15 Degrell I, Nagy E. Correlations between cisternal CSF and plasma concentrations of HVA, MHPG, 50HIAA, DA, and NA.  Biol Psychiatry. 1990;  27 1179-1182
• 16 Derendorf H, Mollmann H, Barth J, Mollmann C, Tunn S, Krieg M. Pharmacokinetics and oral bioavailability of hydrocortisone.  J Clin Pharmacol. 1991;  31 473-476
• 17 Dommisse C S, Schulz S C, Narasimhachari N, Blackard W G, Hamer R M. The neuroendocrine and behavioral response to dextroamphetamine in normal individuals.  Biol Psychiatry . 1984;  19 1305-1315
• 18 Gardner E L. Brain Reward Mechanisms. In Lowinson JH, Ruiz P, Millman RB, editors Substance Abuse: A Compehensive Textbook. 2nd Ed Williams & Wilkins Baltimore, MD; 1992: 70-99
• 19 Goeders N E. A neuroendocrine role in cocaine reinforcement.  Psychoneuroendocrinology. 1997;  22 237-259
• 20 Goeders N E. The HPA axis and cocaine reinforcement.  Psychoneuroendocrinology . 2002;  27 13-33
• 21 Goeders N E, Guerin G F. Effects of surgical and pharmacological adrenalectomy on the initiation and maintenance of intravenous cocaine self-administration in rats.  Brain Res . 1996;  722 145-152
• 22 Griffing G T, Allen J, Pratt H, Melby J C. Discordance of plasma DHEA-S, DHEA, and cortisol responses with various ACTH regimens.  Metabolism. 1985;  34 631-636
• 23 Guideri G. Death in ventricular fibrillation induced by isoproterenol in DOCA-salt pretreated rats preceded by changes in myocardial electrolytes.  Life Sci . 1983;  33 1353-1362
• 24 Harris D S, Baggott M, Mendelson J H, Mendelson J E, Jones R T. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.  Psychopharmacology . 2002;  162 396-405
• 25 Harris D S, Reus V I, Wolkowitz O M, Mendelson J E, Jones R T. Altering cortisol level does not change the pleasurable effects of methamphetamine in humans.  Neuropsychopharmacology . 2003;  28 1677-1684
• 26 Hung T T, LeMaire W J. The effects of corticotropin, opioid peptides and crude pituitary extract on the production of dehydroepiandrosterone and corticosterone by mature rat adrenal cells in tissue culture.  J Steroid Biochem . 1988;  29 721-726
• 27 Imperato A, Puglisi-Allegra S, Casolini P, Zocchi A, Angelucci L. Stress-induced enhancement of dopamine and acetylcholine release in limbic structures: role of corticosterone.  Eur J Pharmacol . 1989;  165 337-338
• 28 Jouhaneau-Bowers M, Le Magnen J. ACTH self-administration in rats.  Pharmacol Biochem Behav . 1979;  10 325-328
• 29 King G R, Ellinwood E H. Amphetamines and Other Stimulants. In Lowinson JH, Ruiz P, Millman RB, editors Substance Abuse A Comprehensive Handbook. 2nd Ed Williams & Wilkins Baltimore; 1992: 247-270
• 30 Kopin I J, Jimerson D C, Markey S P, Ebert M H, Polinsky R J. Disposition and metabolism of MHPG in humans: application to studies in depression.  Pharmacopsychiatry . 1984;  17 3-8
• 31 Kroboth P D, Salek F S, Pittenger A L, Fabian T J, Frye R F. DHEA and DHEA-S: a review.  J Clin Pharmacol . 1999;  39 327-348
• 32 Kvetnansky R, Pacak K, Fukuhara K, Viskupic E, Hiremagalur B, Nankova B. et al . Sympathoadrenal system in stress. Interaction with the hypothalamic-pituitary-adrenocortical system.  Ann N Y Acad Sci . 1995;  771 131-158
• 33 Lavicky J, Dunn A J. Corticotropin-releasing factor stimulates catecholamine release in hypothalamus and prefrontal cortex in freely moving rats as assessed by microdialysis.  J Neurochem . 1993;  60 602-612
• 34 Liu P S, Lin M K, Hsieh H L. Dehydroepiandrosterone sulfate inhibition of catecholamine secretion from bovine adrenal chromaffin cells.  Neurosci Lett . 1996;  204 181-184
• 35 Lobo R A, Granger L R, Paul W L, Goebelsmann U, Mishell DR J r. Psychological stress and increases in urinary norepinephrine metabolites, platelet serotonin, and adrenal androgens in women with polycystic ovary syndrome.  Am J Obstet Gynecol . 1983;  145 496-503
• 36 Loose D S, Stover E P, Feldman D. Ketoconazole binds to glucocorticoid receptors and exhibits glucocorticoid antagonist activity in cultured cells.  J Clin Invest . 1983;  72 404-408
• 37 Lupien S, Richter R, Risch S C, Mirow A, Gillin J C, Hauger R L. Time course of the corticosteroid-dopaminergic interaction during metyrapone and dexamethasone administration.  Psychiatry Res . 1995;  58 23-35
• 38 Martin S D, Yeragani V K, Lodhi R, Galloway M P. Clinical ratings and plasma HVA during cocaine abstinence.  Biol Psychiatry. 1989;  26 356-362
• 39 Matsuzaki I, Takamatsu Y, Moroji T. The effects of intracerebroventricularly injected corticotropin-releasing factor (CRF) on the central nervous system: behavioural and biochemical studies.  Neuropeptides . 1989;  13 147-155
• 40 Monnet F P, Mahe V, Robel P, Baulieu E E. Neurosteroids, via sigma receptors, modulate the [3H]norepinephrine release evoked by N-methyl-D-aspartate in the rat hippocampus.  Proc Natl Acad Sci USA . 1995;  92 3774-3778
• 41 Moszczynska A, Fitzmaurice P, Ang L, Kalasinsky K S, Schmunk G A, Peretti F J. et al . Why is parkinsonism not a feature of human methamphetamine users?.  Brain . 2004;  127 (Pt 2) 363-370
• 42 Murray H E, Gillies G E. Differential effects of neuroactive steroids on somatostatin and dopamine secretion from primary hypothalamic cell cultures.  J Neuroendocrinol . 1997;  9 287-295
• 43 Oswald L M, Wong D F, McCaul M, Zhou Y, Kuwabara H, Choi L, Brasic J, Wand G S. Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine.  Neuropsychopharmacology . 2005;  30 821-832
• 44 Peroutka S J, Newman H, Harris H. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users.  Neuropsychopharmacology . 1988;  1 273-277
• 45 Piazza P V, Marinelli M, Jodogne C, Deroche V, Rouge-Pont F, Maccari S. Inhibition of corticosterone synthesis by Metyrapone decreases cocaine-induced locomotion and relapse of cocaine self-administration.  Brain Res . 1994;  658 259-264
• 46 Porter J R, Abadie J M, Wright B E, Browne E S, Svec F. The effect of discontinuing dehydroepiandrosterone supplementation on Zucker rat food intake and hypothalamic neurotransmitters.  Int J Obes Relat Metab Disord . 1995;  19 480-488
• 47 Posener J A, Schatzberg A F, Williams G H, Samson J A, McHale N L, Bessette M P. et al . Hypothalamic-pituitary-adrenal axis effects on plasma homovanillic acid in man.  Biol Psychiatry . 1999;  45 222-228
• 48 Posener J A, Schildkraut J J, Williams G H, Gleason R E, Salomon M S, Mecheri G. et al . Acute and delayed effects of corticotropin-releasing hormone on dopamine activity in man.  Biol Psychiatry . 1994;  36 616-621
• 49 Rabkin S W, Fung A Y. Increased sensitivity to norepinephrine cardiac arrhythmias in the deoxycorticosterone acetate high salt rat before the onset of hypertension.  Can J Physiol Pharmacol . 1984;  62 605-609
• 50 Rotllant D, Ons S, Carrasco J, Armario A. Evidence that metyrapone can act as a stressor: effect on pituitary-adrenal hormones, plasma glucose and brain c-fos induction.  Eur J Neurosci . 2002;  16 693-700
• 51 Rupprecht R, Strohle A, Hermann B, di Michele F, Spalletta G, Pasini A. et al . Neuroactive steroid concentrations following metyrapone administration in depressed patients and healthy volunteers.  Biol Psychiatry . 1998;  44 912-914
• 52 Shekim W O, Javaid J, Davis J M, Bylund D B. Urinary MHPG and HVA excretion in boys with attention deficit disorder and hyperactivity treated with d-amphetamine.  Biol Psychiatry . 1983;  18 707-714
• 53 Sherer M A. Intravenous cocaine: psychiatric effects, biological mechanisms.  Biol Psychiatry . 1988;  24 865-885
• 54 Soderpalm A, Nikolayev L, de Wit H. Effects of stress on responses to methamphetamine in humans.  Psychopharmacology (Berl) . 2003;  170 188-199
• 55 Solowij N, Hall W, Lee N. Recreational MDMA use in Sydney: a profile of ‘Ecstacy’ users and their experiences with the drug.  Br J Addict . 1992;  87 1161-1172
• 56 Steketee J D, Goeders N E. Pretreatment with corticosterone attenuates the nucleus accumbens dopamine response but not the stimulant response to cocaine in rats.  Behav Pharmacol . 2002;  13 593-601
• 57 Suzuki A, Hashino M, Chiba H, Saito H, Notake Y, Yanaihara T. et al . Correlation between the levels of catecholamines (noradrenaline, adrenaline) and adrenal steroids (DHA-S, cortisol) in maternal and fetal blood during pregnancy and labor.  Nippon Naibunpi Gakkai Zasshi . 1989;  65 704-714
• 58 Tella S R. Effects of monoamine reuptake inhibitors on cocaine self-administration in rats.  Pharmacol Biochem Behav . 1995;  51 687-692
• 59 Ventura R, Cabib S, Alcaro A, Orsini C, Puglisi-Allegra S. Norepinephrine in the prefrontal cortex is critical for amphetamine-induced reward and mesoaccumbens dopamine release.  J Neurosci . 2003;  23 1879-1885
• 60 Wachtel S R, Charnot A, de Wit H. Acute hydrocortisone administration does not affect subjective responses to d-amphetamine in humans.  Psychopharmacology (Berl) . 2001;  153 380-388
• 61 Ward A S, Collins E D, Haney M, Foltin R W, Fischman M W. Ketoconazole attenuates the cortisol response but not the subjective effects of smoked cocaine in humans.  Behav Pharmacol . 1998;  9 577-586
• 62 Wolkowitz O, Sutton M, Koulu M, Labarca R, Wilkinson L, Doran A. et al . Chronic corticosterone administration in rats: behavioral and biochemical evidence of increased central dopaminergic activity.  Eur J Pharmacol . 1986;  122 329-338
• 63 Wolkowitz O M, Doran A, Breier A, Roy A, Pickar D. Specificity of plasma HVA response to dexamethasone in psychotic depression.  Psychiatry Res. 1989;  29 177-186
• 64 Wolkowitz O M, Sutton M E, Doran A R, Labarca R, Roy A, Thomas J W. et al . Dexamethasone increases plasma HVA but not MHPG in normal humans.  Psychiatry Res . 1985;  16 101-109
• 65 Yen S S, Morales A J, Khorram O. Replacement of DHEA in aging men and women. Potential remedial effects.  Ann N Y Acad Sci . 1995;  774 128-142
• 66 Young E A, Akil H, Haskett R F, Watson S J. Evidence against changes in corticotroph CRF receptors in depressed patients.  Biol Psychiatry . 1995;  37 355-363